Valeritas (NASDAQ:VLRX) has been given a $4.00 target price by equities research analysts at Oppenheimer in a research note issued on Tuesday, August 7th. The brokerage presently has a “buy” rating on the stock. Oppenheimer’s price objective points to a potential upside of 247.83% from the stock’s current price.
Other research analysts have also recently issued reports about the stock. Citigroup assumed coverage on shares of Valeritas in a report on Thursday, July 5th. They issued an “outperform” rating and a $3.50 price target on the stock. ValuEngine raised shares of Valeritas from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, assumed coverage on shares of Valeritas in a report on Thursday, July 5th. They set an “outperform” rating and a $3.50 target price on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Valeritas has an average rating of “Buy” and a consensus price target of $3.67.
NASDAQ:VLRX traded up $0.01 during mid-day trading on Tuesday, hitting $1.15. The stock had a trading volume of 167,000 shares, compared to its average volume of 601,038. The company has a market capitalization of $29.33 million, a P/E ratio of -0.14 and a beta of 4.55. The company has a debt-to-equity ratio of 13.66, a quick ratio of 3.42 and a current ratio of 4.03. Valeritas has a twelve month low of $1.11 and a twelve month high of $6.79.
Institutional investors and hedge funds have recently made changes to their positions in the company. Bainco International Investors bought a new position in Valeritas in the second quarter valued at approximately $228,000. C WorldWide Group Holding A S increased its stake in Valeritas by 28.0% in the second quarter. C WorldWide Group Holding A S now owns 316,194 shares of the company’s stock valued at $424,000 after acquiring an additional 69,216 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in Valeritas in the second quarter valued at approximately $448,000. 7.38% of the stock is currently owned by institutional investors.
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Read More: How to Invest in Marijuana Stocks
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.